How to Find a Drug Rehab Facility: Vetting Criteria and Red Flags

Choosing a drug rehabilitation facility is one of the highest-stakes decisions a person or family will make — and the market offers no shortage of options, ranging from evidence-based clinical programs to operations that exist primarily to collect insurance reimbursements. This page breaks down how to evaluate a facility's legitimacy, what credentials actually mean, and which warning signs have historically preceded patient harm. The difference between a program that works and one that doesn't is rarely obvious from a website.

Definition and scope

A drug rehabilitation facility, in the broadest regulatory sense, is any structured program that provides clinical treatment for substance use disorder (SUD). That umbrella covers medically supervised detox units, residential treatment centers (RTCs), partial hospitalization programs (PHPs), intensive outpatient programs (IOPs), and standard outpatient counseling. Each level corresponds to a different clinical intensity — a distinction formalized by the American Society of Addiction Medicine's ASAM Criteria, the most widely used clinical framework for placement decisions in the United States.

"Rehab" as a colloquial term papers over that entire spectrum. A 28-day residential stay and a weekly outpatient group session are both called rehab. The scope of what a facility can — and should — offer depends entirely on where a patient falls on the ASAM continuum, which ranges from Level 0.5 (early intervention) to Level 4 (medically managed intensive inpatient). Understanding the dimensions and scopes of drug rehab before calling any facility is the single most useful thing a family can do before that first conversation.

How it works

Legitimate facilities operate under state licensure issued by the relevant behavioral health authority — in California, that's the Department of Health Care Services (DHCS); in Texas, it's the Health and Human Services Commission (HHSC). State licensure is the floor, not the ceiling. Accreditation from The Joint Commission or CARF International signals that a facility has undergone independent review of clinical standards, staff qualifications, and patient rights protocols.

Here is a structured checklist for vetting any facility:

1. State license verification — Every state maintains a searchable public database of licensed substance use disorder providers. If a facility doesn't appear in it, that's a hard stop.
2. Accreditation status — Check The Joint Commission's Quality Check tool or CARF's provider search directly. Don't accept a facility's word for it.
3. Staff credentials — Look for licensed clinical social workers (LCSWs), licensed professional counselors (LPCs), or licensed alcohol and drug counselors (LADCs/CADCs). A facility staffed primarily by "coaches" with no clinical licensure is operating well below the standard of care.
4. Medication-assisted treatment (MAT) availability — The Substance Abuse and Mental Health Services Administration (SAMHSA) recognizes buprenorphine, methadone, and naltrexone as evidence-based treatments for opioid use disorder. Facilities that categorically refuse MAT — citing a philosophy that medication is "just trading one addiction for another" — are contradicting the clinical consensus of federal health agencies.
5. Family involvement policy — Research published in sources like the Journal of Substance Abuse Treatment consistently links structured family therapy to better long-term outcomes. A facility that discourages family contact during the entire treatment period warrants scrutiny.
6. Discharge planning — What happens on day 29 of a 28-day program? Facilities without a structured continuum-of-care plan have a demonstrable gap in their model.

For a fuller walkthrough of the intake and treatment process, the how it works overview covers the clinical mechanics in detail.

Common scenarios

Scenario A: Insurance-driven placement. An insurance company approves a specific facility. The family accepts it without verification. This is extremely common and not necessarily wrong — but approval means the facility accepts the insurance, not that it meets clinical standards. A facility can be in-network and still lack accreditation or adequate staffing ratios.

Scenario B: Out-of-state placement. Florida, California, and Arizona historically attracted the highest volume of out-of-state patients partly because of permissive licensing environments in certain periods. The "patient brokering" problem — in which facilities paid third parties to recruit patients, sometimes illegally — prompted Florida to pass the Patient Brokering Act (§817.505, Florida Statutes) with penalties reaching $500,000 per violation. Unsolicited contact from a "counselor" who offers to handle all the logistics, arrange travel, and "find" insurance coverage is a pattern consistent with brokering.

Scenario C: Sober living after residential treatment. Sober living homes are not treatment facilities. They are peer-support housing environments, and most states do not license them as clinical programs. The National Alliance for Recovery Residences (NARR) offers a voluntary certification standard, but compliance is uneven. Families often don't realize there's a categorical difference until something goes wrong.

Decision boundaries

Two facilities can both be licensed and accredited and still be the wrong fit for the same patient. The decision boundary isn't just legitimacy — it's match.

A patient with co-occurring mental health conditions (depression, PTSD, bipolar disorder) needs a facility with dual-diagnosis capability: psychiatrists on staff, not just counselors who acknowledge mental health exists. A patient with a severe opioid use disorder who has overdosed before has a different clinical profile than someone completing a first-ever alcohol detox. ASAM Level 3.7 (clinically managed high-intensity residential) is not the same intervention as Level 2.1 (intensive outpatient), and no amount of amenities or marketing language changes that clinical distinction.

Cost is the other axis. Residential treatment in the United States ranges from roughly $6,000 to over $60,000 for a 30-day stay, depending on setting and services. The SAMHSA National Helpline (1-800-662-4357) provides free referrals to state-funded programs for individuals without insurance or with limited financial resources. Getting help for drug rehab and the drug rehab FAQ address the financial and insurance navigation questions that come up most consistently in this process.